SEC filings and other documents

Strong growth in core segments and technology, with MedSurg spin-off planned for 2027.

Specialty growth, tech innovation, and operational efficiency drive strong performance.

Double-digit revenue and EPS growth, raised guidance, and strong segment performance across the portfolio.

Oncology and biopharma growth, portfolio optimization, and strong financials drive long-term targets.

Record revenue and EPS growth, with raised guidance and strong segment performance.

Record Q1 revenue and profit growth led to higher full-year guidance and robust segment momentum.

Raised guidance and platform growth fueled by automation, specialty, and RxTS expansion.

Margin growth driven by specialty focus, automation, and strong oncology and vision platforms.

Sharpened strategy and raised guidance highlight growth in oncology, specialty, and tech platforms.

Separation of the medical segment and oncology growth drive strong performance amid regulatory shifts.

Record revenue and EPS growth in 2025, with strong 2026 outlook and strategic portfolio moves.

Strong growth in pharma and specialty platforms, with stable long-term EPS outlook and focused capital allocation.

Q3 delivered double-digit profit growth and raised FY25 guidance, with PRISM Vision acquisition announced.